Treatment News : Early Trial Paves the Way for Study of Long-Acting HIV Meds

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 11, 2014

Early Trial Paves the Way for Study of Long-Acting HIV Meds

CROI 2014A study investigating the tolerability and efficacy of the investigational HIV antiretrovirals (ARV) GSK744 and Edurant (rilpivirine) has laid the groundwork for a future trial of long-acting versions of these drugs, MedPage Today reports. This was a Phase IIb trial comparing treatment with the integrase inhibitor GSK744 and the reverse transcriptase inhibitor Edurant to a standard triple regimen of Sustiva (efavirenz) and two nucleoside reverse transcriptase inhibitors (NRTIs). Forty-eight week results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

A total of 181 treatment-naive study participants were divided into three treatment groups who received three respective daily oral doses of GSK744 for 48 weeks: 10, 30 and 60 milligrams. During the first half of the treatment period, the drug was combined with two NRTIs. During the last 24 weeks, the investigators swapped the NRTIs with Edurant.

A comparison group received Sustiva plus two NRTIs for 48 weeks.

The rates of viral suppression between the two study groups was not statistically different, meaning that any apparent difference in the data may have been a result of chance and that the drug regimens appear to be essentially comparable in efficacy. After 48 weeks, 82 percent of those who received at least one dose of the study drugs had achieved and maintained an undetectable viral load, compared with 74 percent of those who received at least one dose of the drugs in the Sustiva group.

A long-acting version of GSK744 is already being investigated as a form of pre-exposure prophylaxis (PrEP) and has shown promise in trials in primates to protect against both vaginal and rectal exposure to HIV (or SIV, HIV’s simian cousin, in the case of the primates). Meanwhile, a long-acting form of Edurant is currently being developed.

This study opens the door for a study of a long-acting therapy with intramuscular injections of GSK744 and Edurant every four to eight weeks.

To read the MedPage Today story, click here.

To read the conference poster, click here.

Search: Conference on Retroviruses and Opportunistic Infections, CROI, HIV, long-acting, GSK744, Edurant, rilpivirine, Sustiva, efavirenz, pre-exposure prophylaxis, PrEP.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.